News & Updates
Filter by Specialty:
Show Multimedia Only

Olanzapine a favourable alternative to dexamethasone for CINV
27 Sep 2021
byAudrey Abella
Olanzapine administered at a dose of 5 mg was noninferior to dexamethasone and is associated with fewer adverse effects than dexamethasone for chemotherapy-induced nausea and vomiting (CINV), according to data presented at ESMO 2021.
Olanzapine a favourable alternative to dexamethasone for CINV
27 Sep 2021
Ribociclib plus letrozole improves OS in hormone receptor–positive, HER2-negative advanced breast cancer
27 Sep 2021
byDr Margaret Shi
A combined regimen of ribociclib plus letrozole as first-line treatment provides a statistically significant and clinically meaningful overall survival (OS) benefit vs placebo plus letrozole in postmenopausal patients with hormone receptor–positive and HER2-negative advanced breast cancer (BC), results of the phase III MONALEESA-2 study have shown.